When a pump company brings out a new pump, wearers using the prior models often want to upgrade to the latest and greatest device for its advancements or improvements in software or hardware. And based on usual industry practice, they expect an upgrade policy that allows them to buy the new pump at a reduced price. Tandem Pump Company recently announced the good news that FDA approval for the new t:slim G4 insulin pump that comes with a built-in Dexcom G4 is expected later this year. This new pump has a new body, new software, and new parts that allow it to display Dexcom G4 data right on the pump screen. Tandem will be ready to ship 30 days after approval.
Ruth Roberts MA
Ruth Roberts, MA, is a medical writer, editor and educational consultant on intensive self-management. She has been involved in diabetes support groups for over 20 years and has coauthored several books on diabetes. She is a professional member of the American Diabetes Association, has served on the Board of Directors for the International Diabetes Athletes Association. She manages business matters and product development for the company. Her expertise in presenting complex information in a clear, easy-to-read format benefits our publications. She worked for 20 years in academic teaching and corporate training before developing the company.
The New Year gives you a great chance to clean the slate and start over with fresh energy for managing your diabetes with insulin on a pump or injections. Some people might call this list resolutions, but we prefer other words. These are areas for you to Review and decide whether to Return, Revise or Refresh.
The Apple Watch and its operating system iOS 8 holds great promise for people with diabetes when it and the iPhone finally connect wearers to Apple’s Health software. With Android options also rapidly developing, these advances hold great potential for easy passage of diabetes data between devices so it can benefit people with diabetes and their health care providers. The question we really want answered is when will the meter, pump and CGM talk to each other?
A provocative article on the front page of the Sunday’s New York Times (April 6, 2014) took on the high cost of diabetes care and investigated several areas of medical advancements as well as outrageous pricing. The article asks startling questions such as: Are your favorite diabetes drugs and devices relevant to your treatment?
So you're having some digestive upset, bloating, diarrhea, and cramping, interspersed with mood shifts with confusion and exhaustion. You monitor the condition, readi up on it, talk with others about it and everything points to a problem with gluten. Is gluten just a buzz word or might it really be causing your gastric distress?
Who does your diabetes data belong to? You - obviously. You're the one who created it and needs it for diabetes management. Your glucose readings, your insulin doses, your carbs and meals consumed, your exercise events, your stress levels, your devices. How can you take charge of your data and benefit from it?
Sodium-glucose transporter-2 (SGLT-2) is the name of a transporter protein in the kidneys that has been a hot topic in diabetes research. In people with normal blood glucose (BG) levels, glucose is not excreted into the urine. The glucose molecules pass from the bloodstream into an area of the kidney called the glomerulus and are actively reabsorbed by SGLT-2 (in an area called the proximal convoluted tubule), rather than being lost into the urine, into the blood to conserve energy. Glucose represents a major body fuel, so any loss of glucose into the urine would be wasteful.